New combo aims to fix chemo side effect in cancer survivors

This study is for adults with certain cancers (like breast, lung, or ovarian) that are in complete remission but have persistently low platelet counts from past chemotherapy. It tests whether adding a vitamin A derivative (ATRA) to a standard platelet-boosting drug works better than the standard drug alone. About 220 participants will receive either the combination or the single drug for 12 weeks, and researchers will track platelet levels and safety.